[{"id":"f5056d6b-3ffd-4e44-961f-b461e0552213","acronym":"A051902","url":"https://clinicaltrials.gov/study/NCT04803201","created_at":"2021-03-17T15:57:46.362Z","updated_at":"2025-02-25T14:15:53.168Z","phase":"Phase 2","brief_title":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT04803201 - A051902","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" TNFRSF8 expression","tags":["PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • azacitidine • cyclophosphamide • etoposide IV • Copiktra (duvelisib) • vincristine • prednisone • Onureg (azacitidine oral) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 10/08/2021","start_date":" 10/08/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-18"},{"id":"fe033f7e-24b3-4288-bdd8-92b0259dd61d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05010005","created_at":"2021-08-18T15:53:40.772Z","updated_at":"2025-02-25T15:27:02.226Z","phase":"Phase 1","brief_title":"A Study of Ruxolitinib and Duvelisib in People With Lymphoma","source_id_and_acronym":"NCT05010005","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD8","pipe":" | ","alterations":" CD8 positive","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • Copiktra (duvelisib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 08/12/2021","start_date":" 08/12/2021","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-10"},{"id":"aa4d2f71-0b09-413a-abc9-1d8702d772bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05065866","created_at":"2021-10-04T12:53:00.645Z","updated_at":"2025-02-25T16:45:37.143Z","phase":"Phase 1","brief_title":"Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy","source_id_and_acronym":"NCT05065866","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ALK • MYC • BCL2 • CD8 • TNFRSF8 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • MYC • BCL2 • CD8 • TNFRSF8 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Copiktra (duvelisib) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 11/18/2021","start_date":" 11/18/2021","primary_txt":" Primary completion: 01/02/2024","primary_completion_date":" 01/02/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-06"},{"id":"8f688b25-930e-42ca-9a40-fca5c6f5662a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04890236","created_at":"2021-05-18T12:01:56.234Z","updated_at":"2025-02-25T15:54:04.644Z","phase":"Phase 1","brief_title":"Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study","source_id_and_acronym":"NCT04890236","lead_sponsor":"Emory University","biomarkers":" CD27","pipe":"","alterations":" ","tags":["CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Copiktra (duvelisib) • Kymriah (tisagenlecleucel-T) • ETP-47187"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 01/13/2022","start_date":" 01/13/2022","primary_txt":" Primary completion: 03/20/2024","primary_completion_date":" 03/20/2024","study_txt":" Completion: 09/04/2024","study_completion_date":" 09/04/2024","last_update_posted":"2025-01-20"},{"id":"62fde8ea-b4f1-4e11-9442-c58db1f54a1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04688658","created_at":"2021-01-19T20:48:11.081Z","updated_at":"2025-02-25T14:29:48.942Z","phase":"Phase 1/2","brief_title":"Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma","source_id_and_acronym":"NCT04688658","lead_sponsor":"John Kirkwood","biomarkers":" BRAF • CD8","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • axitinib • Copiktra (duvelisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 07/21/2021","start_date":" 07/21/2021","primary_txt":" Primary completion: 02/22/2024","primary_completion_date":" 02/22/2024","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-08-08"},{"id":"8daa166e-7414-41bf-92cd-493c1f6c451c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03961672","created_at":"2021-01-18T19:29:37.641Z","updated_at":"2024-07-02T16:35:19.292Z","phase":"Phase 2","brief_title":"Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT03961672","lead_sponsor":"City of Hope Medical Center","biomarkers":" BCL2 • CCND1 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression","tags":["BCL2 • CCND1 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Copiktra (duvelisib) • ETP-47187"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 05/13/2020","start_date":" 05/13/2020","primary_txt":" Primary completion: 06/27/2024","primary_completion_date":" 06/27/2024","study_txt":" Completion: 06/27/2024","study_completion_date":" 06/27/2024","last_update_posted":"2024-02-15"},{"id":"7de7dfc6-4817-4f79-ad15-0a048f626400","acronym":"","url":"https://clinicaltrials.gov/study/NCT03534323","created_at":"2021-01-18T17:24:36.228Z","updated_at":"2024-07-02T16:35:24.098Z","phase":"Phase 1/2","brief_title":"Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS","source_id_and_acronym":"NCT03534323","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Copiktra (duvelisib)"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 07/12/2018","start_date":" 07/12/2018","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-01-09"},{"id":"c965a0ee-88c0-462a-b555-1823c1aa61cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05057247","created_at":"2021-09-27T12:52:54.895Z","updated_at":"2024-07-02T16:35:26.842Z","phase":"Phase 2","brief_title":"Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC","source_id_and_acronym":"NCT05057247","lead_sponsor":"Glenn J. Hanna","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Copiktra (duvelisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 10/14/2021","start_date":" 10/14/2021","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-12-07"},{"id":"0542097c-f373-45a9-8aee-8c7560f9b729","acronym":"MARIO-3","url":"https://clinicaltrials.gov/study/NCT03961698","created_at":"2021-01-18T19:29:39.309Z","updated_at":"2024-07-02T16:35:40.372Z","phase":"Phase 2","brief_title":"Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma","source_id_and_acronym":"NCT03961698 - MARIO-3","lead_sponsor":"Infinity Pharmaceuticals, Inc.","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • albumin-bound paclitaxel • eganelisib (IPI-549)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 12/17/2019","start_date":" 12/17/2019","primary_txt":" Primary completion: 08/31/2023","primary_completion_date":" 08/31/2023","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2023-08-10"},{"id":"2dfeb986-6721-4504-befe-6a96df34412d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05239910","created_at":"2022-02-15T16:53:13.149Z","updated_at":"2024-07-02T16:36:02.370Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL","source_id_and_acronym":"NCT05239910","lead_sponsor":"Rhizen Pharmaceuticals SA","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • tenalisib (RP6530)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2022-10-17"},{"id":"a7069631-5a6c-4c6d-b80d-c3ff1abc9085","acronym":"","url":"https://clinicaltrials.gov/study/NCT02637531","created_at":"2021-01-18T12:49:44.221Z","updated_at":"2024-07-02T16:36:14.125Z","phase":"Phase 1","brief_title":"A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549","source_id_and_acronym":"NCT02637531","lead_sponsor":"Infinity Pharmaceuticals, Inc.","biomarkers":" HER-2 • ER • ALK • PGR • MSI","pipe":" | ","alterations":" MSI-H/dMMR • ER negative • PGR negative","tags":["HER-2 • ER • ALK • PGR • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • eganelisib (IPI-549)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 219","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-04-04"},{"id":"9dced584-0aa6-4004-960c-2d56af857620","acronym":"SCRI HEMREF 34","url":"https://clinicaltrials.gov/study/NCT01871675","created_at":"2021-01-18T08:23:00.404Z","updated_at":"2024-07-02T16:37:30.738Z","phase":"Phase 1","brief_title":"Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies","source_id_and_acronym":"NCT01871675 - SCRI HEMREF 34","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Copiktra (duvelisib) • bendamustine"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2016-07-11"}]